Parkinson's disease dementia
Current Neurology and Neuroscience Reports, ISSN: 1528-4042, Vol: 10, Issue: 4, Page: 292-298
2010
- 14Citations
- 77Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations14
- Citation Indexes14
- 14
- CrossRef13
- Captures77
- Readers77
- 77
Review Description
Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly slow and incomplete. To significantly affect PDD, novel "disease-modifying" agents, rather than more traditional neurotransmitter replacement approaches, likely will be required. © Springer Science+Business Media, LLC 2010.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955896757&origin=inward; http://dx.doi.org/10.1007/s11910-010-0113-7; http://www.ncbi.nlm.nih.gov/pubmed/20428976; http://link.springer.com/10.1007/s11910-010-0113-7; https://dx.doi.org/10.1007/s11910-010-0113-7; https://link.springer.com/article/10.1007/s11910-010-0113-7; http://www.springerlink.com/index/10.1007/s11910-010-0113-7; http://www.springerlink.com/index/pdf/10.1007/s11910-010-0113-7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know